What is Dasatinib?

Aug 27,2021

Dasatinib, sold under the brand name Sprycel among others, is a targeted therapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+). It is taken by mouth.

Common adverse effects include low white blood cells, low blood platelets, anemia, swelling, rash, and diarrhea. Severe adverse effects may include bleeding, pulmonary edema, heart failure, and prolonged QT syndrome. Use during pregnancy may result in harm to the baby. It is a tyrosine-kinase inhibitor and works by blocking a number of tyrosine kinases such as Bcr-Abl and the Src kinase family.



Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.

Dasatinib is used to treat a certain type of chronic myeloid leukemia (CML; a type of cancer of the white blood cells) as a first treatment and in people who can no longer benefit from other leukemia medications including imatinib (Gleevec) or in those who cannot take these medications because of side effects. Dasatinib is also used to treat a certain type of chronic CML in children. Dasatinib is also used to treat a certain type of acute lymphoblastic leukemia (ALL; a type of cancer of the white blood cells) in people who can no longer benefit from other leukemia medications or who cannot take these medications because of side effects.

Mechanism of action

Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.

How should this medicine be used?

Dasatinib comes as a tablet to take by mouth. It is usually taken once a day, in the morning or in the evening, with or without food. Take dasatinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take dasatinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the tablets whole; do not split, chew, or crush them. Wear latex or nitrile gloves when handling tablets that are accidently crushed or broken to prevent contact with the medication.

Your doctor may adjust your dose or permanently stop your treatment of dasatinib depending on your response to treatment and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment. Continue to take dasatinib even if you feel well. Do not stop taking dasatinib without talking to your doctor.

What side effects can this medication cause?

Dasatinib may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

muscle pain


joint pain

pain, burning or tingling in the hands or the feet


skin redness

peeling skin

swelling, redness, and pain inside the mouth

mouth sores





stomach pain or swelling

loss of appetite

weight loss

  • Related articles
  • Related Qustion
  • Dasatinib: BCR-ABL kinase inhibitor Sep 20, 2023

    Dasatinib, known as Sprycel, is a receptor tyrosine kinase inhibitor developed by Bristol-Myers Squibb Company.

  • Dasatinib: A second-generation BCR-ABL1 tyrosine kinase inhibitor Sep 18, 2023

    Dasatinib is a tyrosine kinase inhibitor indicated for the treatment of chronic myeloid leukemia, but side effects may occur during use

  • The uses and side effects of Dasatinib Aug 21, 2019

    Dasatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.It sold under the brand name Sprycel, is a targeted therapy used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).

See also

Polydeoxyribonucleotide (PDRN) is an agonist of the A2A adenosine receptors.It is DNA derived from a controlled purification and sterilization process of the sperm of Oncorhynchus mykiss (Salmon Trout).....

Aug 27,2021Chemical pesticides ?

Polydeoxyribonucleotides (PDRNs) are a family of DNA-derived drugs with a molecular weight ranging from 50 to 1500 kDa, which are mainly extracted from the sperm cells of salmon trout or chum salmon.....

Aug 30,2021Biochemical Engineering



Dasatinib manufacturers

  • Dasatinib
  • 302962-49-8 Dasatinib
  • $5.00 / 1kg
  • 2023-09-29
  • CAS:302962-49-8
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: 300tons
  • Dasatinib
  • 302962-49-8 Dasatinib
  • $0.00 / 1kg
  • 2023-09-07
  • CAS:302962-49-8
  • Min. Order: 1kg
  • Purity: 99.9% HPLC
  • Supply Ability: 9000
  • Dasatinib
  • 302962-49-8 Dasatinib
  • $500.00 / 1KG
  • 2023-08-16
  • CAS:302962-49-8
  • Min. Order: 1KG
  • Purity: >99%
  • Supply Ability: 50000kg/Month